PATENT CLAIM ANALYSIS

Application Number: 15916617
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "400000"]

Abstract:
The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

Claim (Index 105):
The method of any one of  claims 102  to  104  wherein the 2-fluoroacrylate-divinylbenzene-1,7-octadiene copolymer crosslinked in the salt form is stabilized with a linear polyol.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 90.0
- Lexical Diversity: 2.39062
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14581698', '15287179', '15052193', '15052186', '15472936']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7880963652333496
- 35 USC 102 Novelty (BERT): 0.5972223816407617
- Combined Prediction Score: 0.7690089668740908
- Mean Citation Score: 433.907818
- Max Citation Score: 690.2378
- Similarity Product: 420.391002232504

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test